| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 01/26/2011 | CN101953814A Febuxostat solid preparation |
| 01/26/2011 | CN101953785A Myricetin microemulsion type preparation and preparation method thereof |
| 01/26/2011 | CN101698069B Traditional Chinese medicine preparation for treating cervical vertigo |
| 01/26/2011 | CN101623460B Medicine for treating rheumatic pain and preparation method thereof |
| 01/26/2011 | CN101428096B Chinese medicinal composition for treating femoral head necrosis and preparation method thereof |
| 01/26/2011 | CN101417023B Traditional Chinese medicine for treating lumbar hyperosteogen and preparation thereof |
| 01/26/2011 | CN101301394B Medicament for treating rheumatoid disease |
| 01/26/2011 | CN101274055B Medicament for fumigating rheumatic arthritis and rheumatoid arthritis |
| 01/26/2011 | CN101077875B Boronic ester and acid compounds, synthesis and uses |
| 01/26/2011 | CN101058561B Diphenylurea derivative for inhibiting protein kinase, and composition and use thereof |
| 01/25/2011 | US7875728 Hydrazonopyrazole derivatives and their use as therapeutics |
| 01/25/2011 | US7875727 Benzimidazole vascular damaging agents |
| 01/25/2011 | US7875712 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid |
| 01/25/2011 | US7875614 Phthalazinones |
| 01/25/2011 | US7875590 using an injectable or implantable rod-shaped formulation for delivery of osteogenic proteins to treat osteoporotic and/or osteopenic bone; bone morphogenic proteins |
| 01/25/2011 | US7875585 Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide |
| 01/25/2011 | US7875342 Porous ceramic composite bone grafts |
| 01/25/2011 | US7875298 Kit; leaves of Melissa Officinalis, Eleutherococcus senticosus; Avena sativa, Ballota Nigra, roots of Glycyrrhiza glabra/gan cao, roots of Uncaria Tomentosa; lupus, multiple sclerosis, rheumatoid arthritis, rheumatism, osteoporosis, asthma |
| 01/25/2011 | US7875279 intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis are enriched by deleting or inactivating genes; asthma, morbus Crohn, colitis ulcerosa, multiple sclerosis and chronic bronchitis and immune and auto-immune diseases and allergies and bone diseases and osteoporosis |
| 01/25/2011 | CA2476983C Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
| 01/25/2011 | CA2458690C Pharmaceutical compositions comprising an ascomycin derivative |
| 01/25/2011 | CA2457856C Sulphonated meso-tetraphenyl chlorins and their use as therapeutic agents |
| 01/25/2011 | CA2454532C Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 01/25/2011 | CA2447765C 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 01/25/2011 | CA2436599C Oral pharmaceutical compositions comprising polyvinylpyrrolidone (pvp) and 5-cnac |
| 01/25/2011 | CA2434299C Tricyclic androgen receptor modulator compounds and methods |
| 01/25/2011 | CA2432582C Sulfamidothienopyrimidines |
| 01/25/2011 | CA2410000C Compositions and methods comprising plasmid dna for wound healing and for repairing and regenerating tissue |
| 01/25/2011 | CA2388468C Mediators of hedgehog signalling pathways, compositions and uses related thereto |
| 01/25/2011 | CA2385322C A substantially cell membrane impermeable compound and use thereof |
| 01/25/2011 | CA2381882C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/25/2011 | CA2355768C Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 01/25/2011 | CA2317455C Hydroxamic and carboxylic acid derivatives |
| 01/20/2011 | WO2011009075A2 Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 01/20/2011 | WO2011009039A2 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| 01/20/2011 | WO2011008052A2 Composition for the prevention or treatment of bone diseases comprising colforsin daropate |
| 01/20/2011 | WO2011007895A1 Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecaboxylic acid by poor-solvent addition method |
| 01/20/2011 | WO2011007135A1 Use of pro-inflammatory compounds for promoting bone formation |
| 01/20/2011 | WO2010114319A9 Composition for bone regeneration |
| 01/20/2011 | WO2009146490A8 A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k |
| 01/20/2011 | US20110015663 Combination Therapies for the Treatment of Obesity |
| 01/20/2011 | US20110015437 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/20/2011 | US20110015370 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 01/20/2011 | US20110015276 Therapeutical uses of inecalcitol |
| 01/20/2011 | US20110015240 Thiazole derivative and use thereof as vap-1 inhibitor |
| 01/20/2011 | US20110015235 Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors |
| 01/20/2011 | US20110015230 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| 01/20/2011 | US20110015226 Treatment of Energy Utilization Disease |
| 01/20/2011 | US20110015212 Pyrimidinones as pi3k inhibitors |
| 01/20/2011 | US20110015211 Fibrosis inhibitor |
| 01/20/2011 | US20110015200 Nitrogen-containing bycyclic compounds active on chronic pain conditions |
| 01/20/2011 | US20110015195 Aryl ureas with angiogenisis inhibiting activity |
| 01/20/2011 | US20110015184 Vinyl-phenyl derivatives for inflammation and immune-related uses |
| 01/20/2011 | US20110015183 Substituted pyrazole sigma receptor antagonists |
| 01/20/2011 | US20110015178 Amido-Thiophene Compounds and Their Use |
| 01/20/2011 | US20110015171 Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| 01/20/2011 | US20110015170 Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| 01/20/2011 | US20110015157 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 01/20/2011 | US20110015155 Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses |
| 01/20/2011 | US20110015145 Cladribine formulations for improved oral and transmucosal delivery |
| 01/20/2011 | US20110015130 Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
| 01/20/2011 | US20110015127 Targeting complement factor h for treatment of diseases |
| 01/20/2011 | US20110014308 Novel compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders. |
| 01/20/2011 | US20110014279 Bioactive complex compositions and methods of use thereof |
| 01/20/2011 | US20110014266 Expandable, porous apatite/collagen composite, and its production method |
| 01/20/2011 | US20110014265 Implant Improving Local Bone Formation |
| 01/20/2011 | US20110014258 Gradient coating for biomedical applications |
| 01/20/2011 | US20110014251 Microvesicles |
| 01/20/2011 | US20110014244 Inorganic Shaped Bodies And Methods For Their Production And Use |
| 01/20/2011 | US20110014243 Pharmaceutical compositions |
| 01/20/2011 | US20110014213 Human anti-alpha 9 integrin antibody |
| 01/20/2011 | US20110014208 Method of Treating Osteoarthritis with an Antibody to NGF |
| 01/20/2011 | US20110014193 Humanized anti-human alpha 9-integrin antibody |
| 01/20/2011 | US20110014188 TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease |
| 01/20/2011 | US20110014186 Arylsulfonamide-based matrix metalloprotease inhibitors |
| 01/20/2011 | US20110014176 Compounds and method for reducing uric acid |
| 01/20/2011 | US20110014171 Formulation and Method for the Prevention and Treatment of Bone Metastases or Other Bone Diseases |
| 01/20/2011 | US20110014164 Efficient induction of pluripotent stem cells using small molecule compounds |
| 01/20/2011 | US20110014159 Method for obtaining characterized muscle-derived cell populations and uses |
| 01/20/2011 | US20110014153 Reinforced tissue graft |
| 01/20/2011 | DE102009033396A1 Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor, and related procedures and use |
| 01/20/2011 | CA2768368A1 Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 01/20/2011 | CA2768018A1 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
| 01/20/2011 | CA2767826A1 Mesenchymal stem cell differentiation using aniopoietin-like-3 |
| 01/20/2011 | CA2764603A1 Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid by poor-solvent addition method |
| 01/19/2011 | EP2275557A1 Albumin fusion proteins |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275547A2 Polynucleotides and polypeptide sequences involved in the process of bonne remodeling |
| 01/19/2011 | EP2275437A1 Polypeptide and pharmaceutical composition containing the polypeptide |
| 01/19/2011 | EP2275416A1 Biologically active methylene blue derivatives |
| 01/19/2011 | EP2275140A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/19/2011 | EP2275117A1 GLP-1, exendin-4, peptide analogs and uses thereof |
| 01/19/2011 | EP2275116A1 Use of a Pak inhibitor for the treatment of a joint disease |
| 01/19/2011 | EP2275107A2 Combinations for the treatment of diseases involving cell proliferation |
| 01/19/2011 | EP2275102A1 N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 01/19/2011 | EP2274302A2 Compounds and compositions as itpkb inhibitors |
| 01/19/2011 | EP2274006A2 Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same |
| 01/19/2011 | EP2274004A2 In vivo temporal control of activ at able matrix- degrading enzymes |
| 01/19/2011 | EP2273980A2 Pharmaceutical composition with bisphosphonate |
| 01/19/2011 | EP1713489B1 Crystalline form of ibandronate sodium and processes for preparation thereof |